ReviewCurrent opinion in structural biology2023
Structural biology of MCR-1-mediated resistance to polymyxin antibiotics.
Review in Current opinion in structural biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Dual-Mechanism Antimicrobial Peptides from a Nature-Inspired Scaffold.Journal of medicinal chemistry · 2026Article
- Antibiotic resistance mechanisms and global resistance patterns of Pseudomonas aeruginosa in microbial keratitis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Herbal extracts as antibiotic adjuvants against ESKAPE pathogens: mechanisms and therapeutic potential.Engineering microbiology · 2026Review
- Marine Antimicrobial Peptide as a Promising Alternative to Polymyxin B.Marine drugs · 2026Article
- Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli.The Journal of antibiotics · 2026Article
- mcr gene family evolution and structural mechanisms of colistin resistance: from mcr-1 to emerging variants.Archives of microbiology · 2026Review
- Mechanistic basis of antimicrobial resistance mediated by the phosphoethanolamine transferase MCR-1.Nature communications · 2025Article
- Review
- Whole-Genome Sequence Analysis, Probiotic Potential, and Safety Assessment of the Marine BacteriumMarine drugs · 2025Article
- Rhein restores the sensitivity ofFrontiers in microbiology · 2025Article
- Effects of pesticides on soil microbial community structure and nitrogen transformation in tobacco fields affected by root rot.Frontiers in microbiology · 2025Article
- Recent Advances in Antimicrobial Resistance: Insights fromMicroorganisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Polymyxins, a last resort antibiotic, target the outer membrane of pathogens and are used to address the increasing prevalence of multidrug-resistant Gram-negative bacteria. The plasmid-encoded enzyme MCR-1 confers polymyxin resistance to bacteria by modifying the outer membrane. Transferable resistance to polymyxins is a major concern; therefore, MCR-1 is an important drug target. In this review, we discuss recent structural and mechanistic aspects of MCR-1 function, its variants and homologs, and how they are relevant to polymyxin resistance. Specifically, we discuss work on polymyxin-mediated disruption of the outer and inner membranes, computational studies on the catalytic mechanism of MCR-1, mutagenesis and structural analysis concerning residues important for substrate binding in MCR-1, and finally, advancements in inhibitors targeting MCR-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.